An open-label pilot study of apremilast for the treatment of moderate to severe lichen planus: A case series

Journal of the American Academy of Dermatology

Volumn 68, Issue 2, 2013, Pages 255-261

  Paul, Joan ^a   Foss, Clare E ^b   Hirano, Stefanie A ^b   Cunningham, Tina D ^b   Pariser, David M ^a,b  

^a Virginia Clinical Research Inc   (United States)

^b EASTERN VIRGINIA MEDICAL SCHOOL   (United States)

Author keywords

apremilast; interferon ; interleukin; leukotriene B4; lichen planus; treatment; tumor necrosis factor

Indexed keywords

APREMILAST;

ADULT; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; DRUG EFFICACY; DRUG SAFETY; ERYTHEMA; FEMALE; FOLLOW UP; HEART RIGHT BUNDLE BRANCH BLOCK; HUMAN; LICHEN PLANUS; MALE; OPEN STUDY; PILOT STUDY; PRIORITY JOURNAL; SKIN BIOPSY; TREATMENT RESPONSE;

HUMANS; LICHEN PLANUS; PILOT PROJECTS; THALIDOMIDE;

EID: 84872306845     PISSN: 01909622     EISSN: 10976787     Source Type: Journal    
DOI: 10.1016/j.jaad.2012.07.014     Document Type: Article

References (16)

1. J.L. Bolognia, J.L. Jorizzo, and R.P. Rapini Dermatology 2nd ed. 2008 Elsevier Philadelphia, PA
2. W.D. James, T.G. Berger, and D.M. Elston Andrew's diseases of the skin: clinical dermatology 10th ed 2005 WB Saunders Philadelphia (PA)
3. R. Katta Lichen planus Am Fam Physician 61 2000 3319 3324 3327-8
4. A.S. Boyd, and K.H. Neldner Lichen planus J Am Acad Dermatol 25 1991 593 619
5. S. Asch, and G. Goldenberg Systemic treatment of cutaneous lichen planus: an update Cutis 87 2011 129 134
6. B. Cribier, C. Frances, and O. Chosidow Treatment of lichen planus Arch Dermatol 134 1998 1521 1530
7. G. Schett, V.S. Sloan, R.M. Stevens, and P. Schafer Apremilast: a novel PDE4 inhibitor in the treatment of autoimmune and inflammatory diseases Ther Adv Musculoskelet Dis 2 2010 271 278
8. X. Chen, Z. Liu, and Q. Yue The expression of TNF-Alpha and ICAM-1 in lesions of lichen planus and its implication J Huazhong Univ Sci Technolog Med Sci 27 2007 739 741
9. R.P. Usatine, and M. Tinitigan Diagnosis and treatment of lichen planus Am Fam Physician 84 2011 53 60
10. R.P. Baughman, M.A. Judson, R. Ingledue, N.L. Craft, and E.E. Lower Efficacy and safety of apremilast in chronic cutaneous sarcoidosis Arch Dermatol 148 2012 262 264
11. H.-W. Man, P. Schafer, L.M. Wong, R.T. Patterson, L.G. Corral, and H. Raymon Discovery of (S)-N-[2-[1-(3-ethoxy-4-methoxyphenyl)-2- methanesulfonylethyl]-1,3-dioxo-2,3-dihydro-1H-isoindol-4-yl] acetamide (apremilast), a potent and orally active phosphodiesterase 4 and tumor necrosis factor-Alpha inhibitor J Med Chem 52 2009 1522 1524
12. J.N. Gordon, J.D. Prothero, C.A. Thornton, K.M. Pickard, A. Di Sabatino, and P.M. Goggin CC-10004 but not thalidomide or lenalidomide inhibits lamina propria mononuclear cell TNF-α and MMP-3 production in patients with inflammatory bowel disease J Crohns Colitis 3 2009 175 182
13. M. Khobzaoui, H.J. Gutke, and M. Burnet CC-10004 Curr Opin Investig Drugs 6 2005 518 525
14. A.B. Gottlieb, B. Strober, J.G. Krueger, P. Rohane, J.B. Zeldis, and C.C. Hu An open-label, single-Arm pilot study in patients with severe plaque-type psoriasis treated with an oral anti-inflammatory agent, apremilast Curr Med Res Opin 24 2008 1529 1538
15. P.H. Schafer, A. Parton, A.K. Gandhi, L. Capone, M. Adams, and L. Wu Apremilast, a cAMP phosphodiesterase-4 inhibitor, demonstrates anti-inflammatory activity in vitro and in a model of psoriasis Br J Pharmacol 159 2010 842 855
16. R.G. Langley, and C.N. Ellis Evaluating psoriasis with Psoriasis Area and Severity Index, Psoriasis Global Assessment, and Lattice System Physician's Global Assessment J Am Acad Dermatol 51 2004 563 569